N@N

CDEX Inc.: Hospitals Order Multiple ValiMed Units to Enhance Patient Safety and Reduce Narcotic Diversion; CDEX Signs Its First

^{Published on 2009-08-26 06:24:58, Last Modified on 2009-08-26 06:24:59 - Market Wire}
 

TUCSON, AZ--(Marketwire - August 26, 2009) - CDEX Inc. (OTCBB: [ CEXI ]) ([ www.cdexinc.com ]) announces the signing of two multi-unit contracts for the placement of four new ValiMed Units in U.S. hospitals. One of the contracts was for the direct purchase of two units and one contract was a two unit Pay-Per-Use pricing plan that CDEX recently implemented to allow more hospitals to afford this life saving medication safety technology. ValiMed is used to validate "The Right Drug at The Right Dose" when high-risk liquid medications are compounded in a pharmacy setting and also as a verification program to reduce the diversion of return narcotics in hospitals and other healthcare facilities.

"The signing of our first Pay-Per-Use Agreement for multiple units marks the beginning of a new era that puts ValiMed in reach of every hospital no matter size or specialty," said Greg Firmbach, Senior Vice President of CDEX. "Pay-Per-Use pricing is an all inclusive turnkey approach to placing this life-saving technology with equipment, supplies and service all for $2.50 per test or less from the hospitals operating (not capital) budgets. We have brought in another sales consultant to accommodate the growing interest and enthusiasm in the marketplace for this innovative pricing model."

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at [ mphilips@cdex-inc.com ].

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements